Gain Therapeutics (NASDAQ:GANX) Earns Buy Rating from HC Wainwright
Gain Therapeutics (NASDAQ:GANX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 236.13% from the company’s previous close. A […]
Gain Therapeutics (NASDAQ:GANX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 236.13% from the company’s previous close. A […]
